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(IV) antibiotic treatment did not change signiﬁcantly before and after 12 months of
TOBI, the number of oral antibiotic treatment days was reduced signiﬁcantly (27.2
vs 20.1; p< 0.001). Overall when comparing the mean predicted FEV1 before 12
months from TOBI start with that after 12 months, no signiﬁcant change was found.
Between the 12 months before and TOBI start, mean FEV1 showed a decrease of
3.5% of the predicted value (from 69.1% to 66.7%), while 6 months after TOBI
start, it increased to 68.3%. This increase was most apparent in patients of 13
to 18 years of age (from 74.5% to 78.6%). After the second other 6 months of
treatment, mean predicted FEV1 showed a slight decrease (−1.6%). During 12
months of follow-up, 12% of patients interrupted TOBI because of side effects
(mainly tinnitus, bronchospasm, dysphonia).
Conclusions: Our study showed that TOBI seems to stabilise the mean value
of predicted FEV1 after 12 months of treatment but does not increase it. TOBI
treatment did not have a signiﬁcant effect in reducing neither the days of IV
antibiotics nor those of hospitalisation, while it was associated with a decrease in
the length of oral antibiotic treatment. Post-marketing surveillance studies have an
important role in describing the effectiveness of treatment in the real non-controlled
clinical context.
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CF patients have lung inﬂammation and infection beginning early in life. This leads
to an irreversible structural damage that is heterogenously distributed throughout the
lung. Adequate monitoring of CF lung disease is paramount to tailoring treatment to
a patient’s need. Pulmonary function tests are insensitive to detect localized or early
damage. Computed Tomography (CT) is the most sensitive tool to detect structural
abnormalities at an early stage of CF lung disease.
Important structural changes that can be detected at an early stage are airway wall
thickening, air trapping, bronchiectasis, and mucus plugging.
Chronic inﬂammation leads to airway wall thickening which is present in young
children with CF. This is more severe in peripheral than in central airways. On CT
peripheral airways cannot be observed directly because they are too small relative to
the CT resolution; they can be identiﬁed indirectly as hypodens areas on expiratory
chest CT representing air trapping areas often combined with hypoperfusion. Mucus
plugging and bronchiectasis are other important structural changes, the latter being
an irreversible and progressive widening of an airway becoming evident in the
majority of patients in childhood. The goldstandard to diagnose bronchiectasis is
through a volumetric CT scan taken at end-inspiration.
Monitoring with CT should start in infancy at regular time interval. Unfortunately,
there are some major hurdles to overcome in young children: (1) CT should only
be done in radiology departments with experience in using the lowest possible
radiation dose; (2) life long radiation exposure should be limited to acceptable
levels. Radiation dose has been brought down substantially in the last decade and
it is likely that it will be further reduced in the near future. A CT scan should
be done at end inspiration and end expiration during a breath hold; in children
younger than 4 yrs the procedure should be done under general anesthesia. This
requires a dedicated team with experience in using the controlled volume technique.
The risk of atelectasis can be avoided when the CT is made using a modern fast
scanner during spontaneous breathing that allow to do a whole CT scan in less
than 1 second. The sensitivity of this method to diagnose air trapping is probably
less compared to the controlled volume technique. In children older than 4 yrs it
is possible to do a whole lung in- and expiratory scan each during a breath hold.
Only few therapeutic studies in young children are available that included chest CT.
Hence, how to deal with abnormalities observed on CT scans of young children
is not straight forward. When the CT scan is normal the pulmonary condition is
probably good; if major abnormalities are being observed more aggressive therapy
should be considered.
R28 EUROPEAN CYSTIC FIBROSIS SOCIETY CONSENSUS ON
GENETIC TESTING
M. Schwarz, C. Castellani, H. Cuppens, Jr M. Macek, J.J. Cassiman, E. Kerem,
P. Durie, E. Tullis, B.M. Assael, C. Bombieri, A. Brown, T. Casals, M. Claustres,
G. Cutting, J. Dodge, I. Doull, P. Farrell, C. Ferec, E. Girodon, M. Johannesson,
B. Kerem, M. Knowles, A. Munck, P.F. Pignatti, D. Radojkovic, P. Rizzotti,
M. Stuhrman, M. Tzetis, J. Zielenski, J.S. Elborn
This paper describes the conclusions of a consensus conference to address the use
and interpretation of CF mutation analysis in the clinical setting.
The limitations of genotyping technology, the choice of mutations to be tested, the
clinical context in which the test is being taken can all inﬂuence how genetic
information is interpreted. Although the diagnosis of cystic ﬁbrosis is usually
straightforward, care needs to be exercised in the use and interpretation of genetic
tests; genotype information is not the ﬁnal arbiter of a clinical diagnosis of cystic
ﬁbrosis or cystic ﬁbrosis transmembrane regulator protein related disorders. The di-
agnosis of these conditions is primarily based on the clinical picture, and supported
by measurements of CFTR function (sweat testing, nasal potential difference and so
on) and genetic analysis. None of these is sufﬁcient on its own to make a diagnosis
of CF or CFTR related disorders.
The consensus addressed the prognostic value of particular genotypes and concluded
that, although useful in group studies, individual genotype can not accurately predict
the pulmonary outcomes in people with CF.
Genotype analysis is a very valuable tool in the diagnosis and assessment of people
with cystic ﬁbrosis and CFTR related disorders; the availability of relatively cheap
DNA sequencing of the entire CFTR gene has thrown up numerous novel mutations
and sequence variants but these must be interpreted with due acknowledgement of
the limitations of primary DNA sequence analysis.
Finally, and of paramount importance, good communication between clinicians and
medical genetic laboratories is vital. Information must be exchanged clearly and
completely between the laboratory and the clinician, and subsequently communi-
cated to the patient in an understandable way.
